Paper35323367
Evaluation of Patient-Reported Outcome Differences by Radiotherapy Techniques for Bone Metastases in A Population-Based Healthcare System.
Olson RA and 5 others. Curr Oncol, 2022. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Evaluation of Patient-Reported Outcome Differences by Radiotherapy Techniques for Bone Metastases in A Population-Based Healthcare System. Papers, record 35323367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35323367
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Evaluation of Patient-Reported Outcome Differences by Radiotherapy Techniques for Bone Metastases in A Population-Based Healthcare System.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Radiotherapy, Conformal | Major topic |
| Radiotherapy, Intensity-Modulated | Major topic |
| Delivery of Health Care | |
| Humans | |
| Pain | |
| Patient Reported Outcome Measures | |
| Quality of Life |
Source PubMed
References19
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30849005 | Trends in Radiation for Bone Metastasis During a Period of Multiple National Quality Improvement Initiatives. | J Oncol Pract | 2019 | https://conductscience.org/library/papers/30849005 | PubMed |
| 2 | 22130630 | Update on the systematic review of palliative radiotherapy trials for bone metastases. | Clin Oncol (R Coll Radiol) | 2012 | https://conductscience.org/library/papers/22130630 | PubMed |
| 3 | 21277118 | Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. | Int J Radiat Oncol Biol Phys | 2011 | https://conductscience.org/library/papers/21277118 | PubMed |
| 4 | 35106919 | Patterns of the use of advanced radiation therapy techniques for the management of bone metastases and the associated factors in Victoria. | J Med Imaging Radiat Oncol | 2022 | https://conductscience.org/library/papers/35106919 | PubMed |
| 5 | 31930016 | SABR-COMET: a new paradigm of care lights up the twilight of metastatic disease. | Ann Transl Med | 2019 | https://conductscience.org/library/papers/31930016 | PubMed |
| 6 | 26281828 | Impact of Using Audit Data to Improve the Evidence-Based Use of Single-Fraction Radiation Therapy for Bone Metastases in British Columbia. | Int J Radiat Oncol Biol Phys | 2016 | https://conductscience.org/library/papers/26281828 | PubMed |
| 7 | 33309977 | Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial. | Int J Radiat Oncol Biol Phys | 2021 | https://conductscience.org/library/papers/33309977 | PubMed |
| 8 | 34068400 | Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care. | Curr Oncol | 2021 | https://conductscience.org/library/papers/34068400 | PubMed |
| 9 | 30982687 | Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. | Lancet | 2019 | https://conductscience.org/library/papers/30982687 | PubMed |
| 10 | 32370765 | Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. | BMC Cancer | 2020 | https://conductscience.org/library/papers/32370765 | PubMed |
| 11 | 31426760 | Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. | BMC Cancer | 2019 | https://conductscience.org/library/papers/31426760 | PubMed |
| 12 | 25035213 | Use of single- versus multiple-fraction palliative radiation therapy for bone metastases: population-based analysis of 16,898 courses in a Canadian province. | Int J Radiat Oncol Biol Phys | 2014 | https://conductscience.org/library/papers/25035213 | PubMed |
| 13 | 34126044 | Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/34126044 | PubMed |
| 14 | 32584700 | Advanced Radiation Therapy Technology Use in the Treatment of Bone Metastases in a Public, Salary-Funded, Non-Incentivized Health Care System. | JCO Oncol Pract | 2021 | https://conductscience.org/library/papers/32584700 | PubMed |
| 15 | 29264976 | Provincial development of a patient-reported outcome initiative to guide patient care, quality improvement, and research. | Healthc Manage Forum | 2018 | https://conductscience.org/library/papers/29264976 | PubMed |
| 16 | 35017007 | Quality of Life After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases. | Int J Radiat Oncol Biol Phys | 2022 | https://conductscience.org/library/papers/35017007 | PubMed |
| 17 | 27072939 | Comparison of patient-reported outcomes with single versus multiple fraction palliative radiotherapy for bone metastasis in a population-based cohort. | Radiother Oncol | 2016 | https://conductscience.org/library/papers/27072939 | PubMed |
| 18 | 31660894 | SUPR-3D: A randomized phase iii trial comparing simple unplanned palliative radiotherapy versus 3d conformal radiotherapy for patients with bone metastases: study protocol. | BMC Cancer | 2019 | https://conductscience.org/library/papers/31660894 | PubMed |
| 19 | 32484754 | Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/32484754 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42032485 | SPINAL: study protocol for a multicenter non-inferiority trial evaluating reduce vertebral irradiation volumes in palliative radiotherapy for spinal bone metastases on analgesic efficacy. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42032485 | PubMed |
| 35621686 | Striving to Fill in Gaps between Clinical Practice and Standards: The Evolution of a Pan-Canadian Approach to Patient-Reported Outcomes Use. | Curr Oncol | 2022 | https://conductscience.org/library/papers/35621686 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35323367
GET https://conductscience.org/api/papers/v1/35323367/authors